{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:27:44Z","timestamp":1790404064800,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","award":["DOC 16-009"],"award-info":[{"award-number":["DOC 16-009"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ejca.2018.09.026","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T19:42:57Z","timestamp":1540842177000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort"],"prefix":"10.1016","volume":"105","author":[{"given":"M.","family":"Kandel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Allayous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dalac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Leccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Lacour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Legoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lesimple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Brunet-Possenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Arnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Granel-Brocard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.E.","family":"Stoebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Maubec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rotolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ballon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Michiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lebbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Borget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.09.026_bib1","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.026_bib2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.026_bib3","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.026_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.09.026_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.09.026_bib6","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.026_bib7","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.026_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.026_bib9","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Dummer","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.026_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/CMR.0b013e3282f36203","article-title":"The economic burden of melanoma in France: assessing healthcare use in a hospital setting","volume":"18","author":"Chevalier","year":"2008","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2018.09.026_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1756-9966-31-91","article-title":"The cost of unresectable stage III or stage IV melanoma in Italy","volume":"31","author":"Maio","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejca.2018.09.026_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/CMR.0b013e32835e58d6","article-title":"The burden of metastatic melanoma: treatment patterns , healthcare use ( utilization ), and costs","author":"Reyes","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2018.09.026_bib13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3747\/co.22.2557","article-title":"Population-based estimates of survival and cost for metastatic melanoma","volume":"22","author":"McCarron","year":"2015","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejca.2018.09.026_bib14","first-page":"1","article-title":"Hospitalisation costs of metastatic melanoma in France ; the MELISSA study (\u00a0MELanoma in hoSpital coSts Assessment )","author":"Fernandes","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.ejca.2018.09.026_bib15","first-page":"1","article-title":"Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands","author":"Franken","year":"2018","journal-title":"Anti Cancer Drugs"},{"issue":"6","key":"10.1016\/j.ejca.2018.09.026_bib16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40258-017-0347-5","article-title":"Estimated healthcare costs of melanoma in Australia over 3 Years post-diagnosis","volume":"15","author":"Elliott","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.ejca.2018.09.026_bib17","series-title":"Choix m\u00e9thodologiques pour l \u2019 \u00e9valuation \u00e9conomique \u00e0 la HAS","author":"Haute autorit\u00e9 de sant\u00e9","year":"2011"},{"key":"10.1016\/j.ejca.2018.09.026_bib18","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2018.09.026_bib19","series-title":"NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data","author":"Latimer","year":"2011"},{"key":"10.1016\/j.ejca.2018.09.026_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/505302","article-title":"Targeted therapies compared to dacarbazine for treatment of brafv600e metastatic melanoma: a cost-effectiveness analysis","volume":"2015","author":"Shih","year":"2015","journal-title":"J Skin Cancer"},{"key":"10.1016\/j.ejca.2018.09.026_bib21","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/bjd.14152","article-title":"A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting","volume":"173","author":"Matter-Walstra","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2018.09.026_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0107255","article-title":"Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma","volume":"9","author":"Curl","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2018.09.026_bib23","first-page":"1","article-title":"Cost-effectiveness analysis in R using a multi-state modeling survival analysis framework: a tutorial","author":"Williams","year":"2016","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.ejca.2018.09.026_bib24","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v038.i07","article-title":"Mstate: an R package for the analysis of competing risks and multi-state models","volume":"38","author":"de Wreede","year":"2011","journal-title":"J Stat Software"},{"key":"10.1016\/j.ejca.2018.09.026_bib25","article-title":"parfm: an R package for parametric frailty models","volume":"51","author":"Munda","year":"2011","journal-title":"J Stat Software"},{"key":"10.1016\/j.ejca.2018.09.026_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.026_bib27","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.026_bib28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2018.09.026_bib29","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2016.11.021","article-title":"Dutch melanoma treatment registry: quality assurance in the care of patients with metastatic melanoma in The Netherlands","volume":"72","author":"Jochems","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.09.026_bib30","series-title":"Efficience de la prise en charge par l \u2019 assurance maladie de la sp\u00e9cialit\u00e9 Cotellic \u00ae (cobimetinib) en association \u00e0 Zelboraf \u00ae (vemurafenib) dans le traitement du m\u00e9lanome avanc\u00e9 (non r\u00e9s\u00e9cable ou m\u00e9tastatique)","author":"Haute autorit\u00e9 de sant\u00e9","year":"2016"},{"key":"10.1016\/j.ejca.2018.09.026_bib31","series-title":"Efficience de la prise en charge par l\u2019assurance maladie de la sp\u00e9cialit\u00e9 MEKINIST (trametinib) en association au TAFINLAR (dabrafenib) dans le traitement du m\u00e9lanome avanc\u00e9 (non r\u00e9s\u00e9cable ou metastatique)","author":"Haute autorit\u00e9 de sant\u00e9","year":"2016"},{"key":"10.1016\/j.ejca.2018.09.026_bib32","series-title":"Efficience de la prise en charge par l \u2019 assurance maladie de la sp\u00e9cialit\u00e9 OPDIVO (nivolumab) dans le traitement du m\u00e9lanome avanc\u00e9 (non r\u00e9s\u00e9cable ou m\u00e9tastatique)33","first-page":"1","author":"Haute autorit\u00e9 de sant\u00e9","year":"2016"},{"key":"10.1016\/j.ejca.2018.09.026_bib33","series-title":"Efficience de la prise en charge par l \u2019 assurance maladie de la sp\u00e9cialit\u00e9 KEYTRUDA (pembrolizumab) dans le traitement du m\u00e9lanome avanc\u00e9 (non r\u00e9s\u00e9cable ou m\u00e9tastatique)","author":"Haute autorit\u00e9 de sant\u00e9","year":"2016"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:22:24Z","timestamp":1760732544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918313960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":33,"alternative-id":["S0959804918313960"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.026","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}